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Abstract: Dithiolopyrrolones are a class of antibiotics that possess the unique 
pyrrolinonodithiole (4H-[1,2] dithiolo [4,3-b] pyrrol-5-one) skeleton linked to two variable 
acyl groups.
 
To date, there are approximately 30 naturally occurring dithiolopyrrolone 
compounds, including holomycin, thiolutin, and aureothricin, and more recently 
thiomarinols, a unique class of hybrid marine bacterial natural products containing a 
dithiolopyrrolone framework linked by an amide bridge with an 8-hydroxyoctanoyl chain 
linked to a monic acid. Generally, dithiolopyrrolone antibiotics have broad-spectrum 
antibacterial activity against various microorganisms, including Gram-positive and  
Gram-negative bacteria, and even parasites. Holomycin appeared to be active against 
rifamycin-resistant bacteria and also inhibit the growth of the clinical pathogen  
methicillin-resistant Staphylococcus aureus N315. Its mode of action is believed to inhibit 
RNA synthesis although the exact mechanism has yet to be established in vitro.
 
A recent 
work demonstrated that the fish pathogen Yersinia ruckeri employs an RNA 
methyltransferase for self-resistance during the holomycin production. Moreover, some 
dithiolopyrrolone derivatives have demonstrated promising antitumor activities.
 
The 
biosynthetic gene clusters of holomycin have recently been identified in S. clavuligerus 
and characterized biochemically and genetically.
 
The biosynthetic gene cluster of 
thiomarinol was also identified from the marine bacterium Pseudoalteromonas sp. SANK 
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73390, which was uniquely encoded by two independent pathways for pseudomonic acid 
and pyrrothine in a novel plasmid. The aim of this review is to give an overview about the 
isolations, characterizations, synthesis, biosynthesis, bioactivities and mode of action of 
this unique family of dithiolopyrrolone natural products, focusing on the period from 1940s 
until now. 
Keywords: dithiolopyrrolone natural products; chemical isolation; total synthesis; 
biosynthesis; mode of action 
 
1. Introduction 
There is an urgent need for new antibiotics with novel cellular targets. Though resistance to existing 
antibiotics is increasing at an alarming rate, only four new structural classes of antibiotics have been 
introduced to the clinic in the last 50 years [1–3]. Dithiolopyrrolones are a group of potent antibiotic 
natural products that have been found in both Gram-negative and Gram-positive bacteria. They consist 
of a unique pyrrolinonodithiole (4H-[1,2] dithiolo [4,3-b] pyrrol-5-one) chromophore [4]. Since the 
isolation of the first member of this family aureothricin (1) from a soil bacterium Streptomyces sp. 26A 
over 65 years ago [5], this class of molecules has intrigued numerous research groups not only for their 
unique chemical structures and their antibacterial/antifungal activities but also the chemical logic and 
regulation of the biosynthesis. Many members of this family have already showed strong  
broad-spectrum activities towards Gram-positive and Gram-negative bacteria, Yeast, Fungi and even 
parasites [6]. Holomycin (9) appeared to inhibit the rafamycin-resistant bacteria. It also acts as 
antibacterial agent toward clinical pathogen methicillin-resistant Staphylococcus aureus N315. Its 
mode of action has been long attributed to inhibit the activity of bacterial RNA polymerase although 
the exact mechanism remained to be elucidated in vitro. In the last two decades, there has been an 
increasing interest in both synthetic and pharmacological investigations of this unique class of 
molecules due to the emerging significance of aryl-containing dithiolopyrrolone as antiproliferative 
agents [7]. 
Despite increasing attention in this rare class of antibiotic natural products, there has been no 
literature to summarize and critically evaluate the scientific conclusions throughout the studies on 
dithiolopyrrolones. This review will give an overview about the discovery and bioactivity, synthesis 
and biosynthesis of this family of rare natural products, covering the period since 1948. Table 1 
provides a summary of the structures of naturally occurring dithiolopyrrolones that were identified  
so far. 
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Table 1. A summary of naturally occurring dithiolopyrrolone antibiotics. 
 
NO. Name 
Structure 
Source Ref. 
R1 R2 R3 
1 Aureothricin CH3CH2CO H CH3 Streptomyces sp. 26A [5] 
2 Thiolutin CH3CO H CH3 Streptomyces albus [6] 
3 Isobutanoylpyrrothine (CH3)2CHCO H CH3 Saccharothrix algeriensis [8] 
4 Butanoylpyrrothine CH3(CH2)2CO H CH3 Saccharothrix algeriensis [9,10] 
5 Senecioylpyrrothine (CH3)2C=CHCO H CH3 Saccharothrix algeriensis [9,10] 
6 Tigloylpyrrothine (CH3)CH=C(CH3)CO H CH3 Saccharothrix algeriensis [9,10] 
7 Xenorhabdin 4 CH3(CH2)4CO H CH3 Xenorhabdus nematophilus XQ1 (ATCC 39497) [11] 
8 Xenorhabdin 5 (CH3)2CH(CH2)3CO H CH3 Xenorhabdus nematophilus XQ1 (ATCC 39497) [11] 
9 Holomycin CH3CO H H Streptomyces griseus (NRRL 2764) [12] 
10 N-Propanoylholothine CH3CH2CO H H Streptomyces sp. P662 [13] 
11 vD844 CHO CH3 H Actinomycete sp. [14] 
12 Xenorhabdin 1 CH3(CH2)4CO H H Xenorhabdus nematophilus XQ1 (ATCC 39497) [11] 
13 Xenorhabdin 2 (CH3)2CH(CH2)3CO H H Xenorhabdus nematophilus XQ1 (ATCC 39497) [11] 
14 Xenorhabdin 3 CH3(CH2)6CO H H Xenorhabdus nematophilus XQ1 (ATCC 39497) [11] 
15 Xenorhabdin 8 decanoyl H H Pseudoalteromonas sp. SANK 73390 [15] 
16 Xenorhabdin 9 dodecanoyl H H Pseudoalteromonas sp. SANK 73390 [15] 
17 Xenorhabdin 10 E-dec-3-enoyl H H Pseudoalteromonas sp. SANK 73390 [15] 
18 Xenorhabdin 11 Z-dec-4-enoyl H H Pseudoalteromonas sp. SANK 73390 [15] 
19 Xenorhabdin 12 E-tetradecenoyl H H Pseudoalteromonas sp. SANK 73390 [15] 
20 Xenorhabdin 13 Z-hexadecenoyl H H Pseudoalteromonas sp. SANK 73390 [15] 
21 Thiomarinol A Marinolic acids A H H Pseudoalteromonas sp. SANK 73390 [16] 
22 Thiomarinol B Marinolic acids B H H Pseudoalteromonas sp. SANK 73390 [17] 
23 Thiomarinol C Marinolic acids C H H Pseudoalteromonas sp. SANK 73390 [17] 
24 Thiomarinol D Marinolic acids D H H Pseudoalteromonas sp. SANK 73390 [18] 
25 Thiomarinol E Marinolic acids E H H Pseudoalteromonas sp. SANK 73390 [18] 
26 Thiomarinol F Marinolic acids F H H Pseudoalteromonas sp. SANK 73390 [18] 
27 Thiomarinol G Marinolic acids G H H Pseudoalteromonas sp. SANK 73390 [18] 
2. Isolation and Characterization 
The family of dithiolopyrrolonenatural products can be divided into three subfamilies: N-methyl,  
N-acylpyrrothine (thiolutin type), N-acylpyrrothine (holomycin type) and thiomarinol, a distinct group 
of PKS-NRPS hybrid antibiotics. In this section, the isolation and structural elucidation will  
be summarized. 
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2.1. N-Methyl, N-Acylpyrrothine (Thiolutin-Type) Derivatives 
The first dithiolopyrrolone natural product, aureothricin (1), was reported in 1948 (Figure 1) [5].
 
Umezawa and co-workers isolated a new strain Streptomyces sp. 26A from a soil sample, collected in 
Mitaka Tokyo, Japan. Subsequently, they found the strain showed a new antibacterial spectrum and a 
yellow crystalline antibiotic substance was extracted. Two years later, the antibiotic thiolutin (2) was 
isolated by a research team in Pfizer, from a soil bacterium Streptomyces albus and described as a 
neutral, optically inactive, yellow-orange substance which appeared to resemble 1 at that time  
(Figure 1) [6]. Accordingly, the arranged interchange of the substances between the two research 
groups led to a conclusion that both compounds belong to the same family of antibiotics but are 
differentiated from their molecular formulas. The empirical formula of C8H8N2O2S2 and C9H10N2O2S2 
for 1 and 2, respectively, were proposed in 1952 (Figure 1) [19]. Both substances were of great interest 
at that time because of their high activity against a variety of fungi, ameboid parasites, Gram-positive,  
Gram-negative and acid fast bacteria [20]. 
Figure 1. N-methyl, N-acylpyrrothine derivatives. 
 
Further study of UV absorption spectrum and chemical degradation [21] led to the elucidation of the 
structure of 2 to be an acetamide of 6-amino-4,5-dihydro-4-methyl-5-oxo-1,2-dithiolo[4,3-b]pyrrole. 
Accordingly, 1 was proposed to be the 3-propionamido derivative of 2, which only differs from the 
length of acyl moiety in 2 (Figure 1). 
Since then, 1 and 2 were repeatedly discovered from various actinomycete strains [22,23]. 
Isobutanoylpyrrothine(ISP) (3) (Figure 1) was first isolated from Streptomyces pimprina along with 1, 
2 and a polyene (heptaene) [8]. More recently, the rare actinomycete strain Saccharothrix algeriensis 
(NRRL B-24137) isolated from a south Algerian soil sample has been found to produce at least five 
dithiolopyrrolone antibiotics including 2 and four other derivatives of 2, isobutanoylpyrrothine(ISP) 
(3), butanoylpyrrothine(BUP) (4), senecioylpyrrothine(SEP) (5) and tigloylpyrrothine(TIP) (6)  
(Figure 1) [9,10]. 3–6 contain the same chromophore of pyrrothine but differ from the acyl groups. The 
same research group also found that addition of organic acids into the semi-synthetic media influenced 
the yield of these dithiolopyrrolones in S. algeriensis [24]. The production of dithiolopyrrolones 
depends upon the nature and concentration of the organic acids in the culture medium. 
Gram-negative bacteria such as symbiotic bacteria Xenorhabdus [11,25] were also found to produce 
thiolutin-type of dithiolopyrrolone natural products. In 1991, McInerney and co-workers [11] 
discovered two new N-methylated dithiolopyrrolone compounds (Figure 1), xenorhabdin 4 (7) and 
xenorhabidin 5 (8), from the culture broth of Xenorhabdusnematophilus XQ1 (ATCC 39497), along 
with other three des-N-methylated analogues 12, 13 and 14 (see next section). X. bovienii is the only 
Xenorhabdus species that was found to produce oxidized xenorxide derivatives, 7a and 8a  
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(Figure 1) [26]. Xenorhabdus are symbiotic enterobacteria associated with insect pathogenic,  
soil-dwelling nematodes of the families Heterorhabditidae and Steinernematidae [27,28]. It is believed 
that they are carried monoxenically within the intestine of the infective stage of the nematode. After 
invading the host insect, the nematodes release a toxin and an inhibitor of the insect immune system, as 
well as releasing Xenorhabdus and other symbionts. The bacterial symbionts, in turn, provide nutrients 
to the nematodes and produce antibiotics which inhibit the growth of other microbial flora in the insect 
cadavers. Intriguingly, Xenorhabdus nematophilus has two growth phases when cultured in the lab but 
only phase one metabolites, including Xenorhabdins, possess a wide spectrum of antibiotic activity. 
2.2. N-Acylpyrrothine (Holomycin Type) Derivatives 
Holomycin 9 (Figure 2) is a des-N-methylthiolutin and was first identified in 1961 from the culture 
broth of a new strain of Streptomyces griseus (NRRL 2764), isolated from a soil sample at Riccino, 
Italy [12]. Although 9 is closely related to 2, these two compounds differ from the physical and 
chemical properties, such as melting points, IR spectrum and behavior under paper chromatographic 
examination. Later on, holomycin and N-propionyl derivative 10 (Figure 2) were isolated from mutant 
strains of Streptomyces sp. P662 [13] and Streptomyces clavuligerus [29]. Interestingly, the wild types 
of these two Streptomyces strains are also producers of cephamycin C, a potent β-lactam antibiotic, 
which is biologically synthesized from aminoadipic acid, cysteine and valine [29–31]. The wild type 
Streptomyces sp. P6621 was found to produce cephamycin C [32] but does not produce 9 and 10. 
Chemical mutagenesis led to generate the mutant Streptomyces sp. P6621-7N49 that only produces 
half the amount of cephamycin C with the production of 9 and 10 [32]. It was proposed that the 
production of 9 and 10 decrease the pool of cysteine available for cephamycin C biosynthesis and thus 
diminishes the level of cephamycin C produced. Streptomyces clavuligerus ATCC27064 has capacity 
to produce two clinically important antibiotics, the β-lactam antibiotic cephamycin C [33] and the  
β-lactamase inhibitor clavulanic acid [34]. Similar to the above case, the production of holomycin 9 in 
the wild type S. clavuligerus is not detectable. The mutant strain IT1, generated by UV mutagenesis of 
the parent strain of S. clavuligerus, led to overproduction of holomycin [29]. It was proposed that the 
unstable genetic element affect the production of holomycin [35]. Holomycin was also found from 
marine Streptomyces sp. M095 which was isolated from a marine sediment sample of Jiaozhou Bay, 
China [36]. 
Figure 2. N-acylpyrrothine derivatives. 
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Gram-negative bacteria were also found to produce holomycin. Recently, the bioassay-guided 
isolation has led to the rediscovery of holomycin from a marine Gram-negative bacterium 
Photobacterium halotolerans S2753 collected from the southern Pacific Ocean [37]. Furthermore, the 
fish pathogen Yersinia ruckeri was also identified to be a holomycin producer, evidenced through 
genome-mining, chemical isolation and characterization approaches [38]. 
In 1969, a new dithiolopyrrolone natural product, antibiotic vD844 (11) (Figure 2), was isolated 
from an unidentified actinomycetes species from a soil sample collected near Copenhagen [14]. 
Interestingly, antibiotic vD844 has an identical molecular formula and molecular weight to holomycin. 
Chemical analysis and X-ray finally elaborated that vD844 was 5-oxo-6-(N-methylformamido)  
4,5-dihydro-1,2-dithiolo[4,3-b] pyrrole [14]. 
The symbiotic bacterium Xenorhabdus nematophilus XQ1 ATCC 39497 was also found to produce 
three holomycin derivatives Xenorhabdin 1 (12), Xenorhabdin 2 (13) and Xenorhabdin 3 (14)  
(Figure 2) [11]. This is the only example among all of the dithiolopyrrolone bacterial producers that 
produces both of thiolutin-type and holomycin-type natural products, indicating that the N-methylation 
may not be tightly regulated in this organism. 
2.3. Thiomarinols, PKS/NRPS Hybrid Antibiotic Natural Products 
Thiomarinols (Figure 3) are a unique subgroup of dithiolopyrrolone natural products in that they are 
hybrid potent antibiotics composed of a dithiolopyrrolone moiety attached via an amid linkage with a 
pseudomonic acid analogue, an esterified unusual fatty acid component connected with the monic acid, 
an important polyketide moiety of an antimethicillin resistant Staphylococcus aureus (MRSA) 
antibiotic mupirocin [39,40]. 
Figure 3. Thiomarinols, hybrid antibiotic natural products. 
 
Pseudoalteromonas is a genus of marine Gram-negative bacterium. The pseudoalteromonas species 
isolated before 1995 were originally part of the alteromonas genus. Psudoalteromondas are known to 
frequently be bioactive [41] and are often found in association with higher eukaryotes or marine 
surfaces [42]. 
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In 1993, a Japanese group first reported the fermentation and isolation of thiomarinol A (21) 
(Figure 3) from a marine Gram-negative bacterium Pseudoalteromonas sp. nov. SANK 73390 isolated 
from seawater [16]. Its molecular formula was first established to be C30H44N2O9S2 with typical UV 
maxima (300 and 387 nm in methanol) of dithiolopyrrolone chromophore. Further NMR analysis 
confirmed that the structure of 21 (Figure 3) is a hybrid of two antibiotics, a pseudomonic acid 
analogue and holothin [43]. Some pseudomonic acid derivatives were also isolated from a marine 
bacterium Alteromonas sp. associated with the marine sponge Darwinella rosacea in 1992 [44]. The 
structure of pseudomonic acid A was identical with that of 21 except for the holothin chromophore 
moiety in 21. Soon after this, six new analogues, thiomarinols B–G (20–27) (Figure 3), were isolated 
from the same strain [17,18]. 
Thiomarinol B 20 [17] possesses the same pseudomonic acid component as 21 but differs in the 
holothin chromophore. The UV spectra and chemical and other spectral properties and X-ray 
confirmed the presence of a sulfone in the difulfide part of holothin in 26, rendering that 26 is the only 
sulfone-containing derivative in the thiomarinol family. The holothin and 7-hydroxyoctanoic acid 
components of 22, 23, 24 and 25 are identical with that of 21 but differ in the modification in the 
monic acid moiety from 21. 27 was determined to be 4-deoxythiomarinol A [18]. Compound 23 was 
found to be 14-homothiomarinol A with one extra methyl in the terminal of the monic acid moiety and 
25 to be 13-ketothiomarinol A. 27 is a hybrid of 6-deoxypseudomonic acid B and holothin [18]. 
Compound 24 is the only thiomarinol derivative containing 8-hydroxynonoic acid moiety but other 
components of holothin and monic acid are identical to 21. More recently, six new xenorhabdin 
derivatives (15–20) (Figure 3) were also found in the culture broth of Pseudoalteromonas SANK73390 
with the different chain length of fatty acid component [15]. 
3. Bioactivities and Possible Mode of Action 
Dithiolopyrrolone natural products possess broad spectrum of biological activities (Table 2). As one 
of the first discovered members, thiolutin (2) has been extensively studied and found that 2 has a wide 
range of activities against a variety of Gram-positive and Gram-negative bacteria, protozoa, yeast, 
pathogenic fungi, and even several human cancer cell lines [45–50]. The later discovered that  
9 showed similar antibacterial profile to thiolutin [13,29].
 
Although the structural difference between 
these two compounds only lies on the methyl group on N4, it is interesting to note that 9 appeared to 
possess no antifungal activity [13,29].
 
Thiomarinols are a special group of dithiopyrrolones, which are 
actually hybrid molecules consisting of one pyrrothine and one psedomonic acid moiety varying in 
length [16–18,51]. Owing to the unique mupirocin-like component in the structure, thiomarinols 
display much higher activity against Staphylococcus aureus, especially the methicillin-resistant  
S. aureus (MRSA), than other dithiolopyrrolones [15]. 
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Table 2. Biological activities of dithiolopyrrolones. 
Organism 
Thiolutin Holomycin Thiomarinol 
MIC (μg/mL)/IC50 (μM)  
G+ 
Bacilius coagulans CIP 6625 <0.2 NC NC 
Bacillus subtilis ATCC 6633 2 NC NC 
Microcoecus leteus ATCC 9314 <0.2 NC NC 
Staphylococcus aureus 20 4 <0.01 
G− 
Klebsiella pneumonia 1 8 0.78 
Escherichia coli >100 <2 3.13 
Salmonella enteric >100 NC NC 
Pseudomanas aeruginosa >100 64 0.39 
Proteus mirabilis NC 4 NC 
Haemophilus influenza NC <0.3 NC 
Fungi 
Mucor ramannianus NRRL 1829 10 NC NC 
Penicillium sp. 20 NC NC 
Alternaria sp. 20 NC NC 
Fusarium <40 NC NC 
Candida albicans 20 NC NC 
Yeast Saccharamyces cerevisiae 10 NA NC 
HUVEC 
VTN 0.83 NC NC 
FN 0.16 NC NC 
COL 0.48 NC NC 
Microbials were tested as MIC and HUVEC were tested as IC50 values. NC, unclear; NA, no activity; 
HUVECs, human umbilical vein endothelial cell; VTN, vitronectin; FN, fibronectin; COL, collagen type IV. 
The mode of action for dithiolopyrrolones has been studied to a great extent using 2/9 as the model 
compounds [29].
 
It was established that the antibacterial activity of 2/9 against E. coli is attributed to 
the inhibition of RNA synthesis [29,52,53]. However, the dispute of whether 2/9 inhibits the initiation 
or elongation steps of RNA synthesis has been argued for a long time [52,54]. Khachatourians and 
Tipper measured the effects of 2 on β-galactosidase expression in E. coli, and suggested that this 
compound inhibits RNA chain elongation [52].
 
In contrast to this conclusion, the study performed by 
Sivasubramanian and Jayaraman indicated that 2 inhibits initiation of RNA transcription [54]. To 
resolve the above discrepancies, the mode of action of dithiolopyrrolones was reinvestigated using 
holomycin as the model [50].
 
By characterizing the effects of 9 on the kinetics of β-galactosidase 
expression, Oliva et al. confirmed that 9 inhibits RNA polymerase at the level of RNA chain 
elongation rather than initiation [50]. More supportive evidence comes from a study characterizing 
activities of various RNA polymerase inhibitors against Staphylococcus aureus mutants that display 
resistance to rifampin, an inhibitor of transcription initiation. O’Neil et al. found that both 2 and 9 are 
both active against S. aureus strains containing mutant RNA polymerase β-subunit (rpoB) gene that 
confers resistance to rifampin [55]. This result suggested that the target site(s) of dithiolopyrrolones is 
different from that of rifampin, and dithiolopyrrolones only affect mRNA transcription at the phase of 
elongation. Recently, an RNA methyltransferase Hom12, which can methylate the RNA and hence 
protect the host from the cytotoxic effect of 9, was characterized in the 9 producing fish pathogen 
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Yersinia ruckeri [38]. This study proposed that RNA methylation may interfere with the activity of 
RNA polymerase by 9, consistent with the finding that the mutant E. coli strain harboring hom12 
showed tolerance to 9. Future studies on the exact RNA substrate of Hom12 and the relationship 
between such RNA species and RNA polymerase will shed light on the in vitro reconstitution of the 
mode of action of holomycin, and therefore the whole dithiolopyrrolone family. 
The mechanism underlying the inhibition of RNA polymerase by dithiolopyrrolones still remains to 
be revealed. However, the structural characteristics of dithiolopyrrolone core scaffold, the  
disulfide-bridged heterocycle, may give some hints to this question. The mycotoxin gliotoxin and the 
histone deacetylase inhibitor FK228 are two compounds that possess a similar disulfide bond [38,56]. 
It was shown that the activities of these molecules are due to the reduction of the disulfide bond in the 
cell, giving rise to the more active dithiol groups which can react with target proteins' thiol  
groups [56,57].
 
By analogy, dithiolopyrrolone compounds may behave in the same way to inhibit RNA 
polymerase. In support of this hypothesis, Li et al. found that there were a number of intermediates, 
with the dithiol groups modified by a combination of mono- and di-S-methylation, accumulating in a 
mutant holomycin producer, in which the gene (hlmI) responsible for the disulfide formation was 
deleted [58]. This result suggested that the dithiol intermediates produced by ΔhlmI mutant may be 
very active even toxic, and the host can protect itself by incapacitating the reactive dithiol groups. 
Beside the above "reduction" mechanism concerning dithiolopyrrolone action mode, an “oxidation” 
mechanism was also proposed. Juhl et al. found that E. coli strains carrying the thdA (sulfone oxidase) 
mutation showed hypersensitivity to thiolutin. Since these thdA mutants possess high oxidation 
activities toward a wide variety of substrates containing sulfur, the authors implied that oxidation of 
thiolutin may induce its toxicity in the cell [59]. 
RNA polymerase represents an attractive target for the development of high-efficiency antibacterial 
drugs because transcription is essential for bacterial growth and survival [60].
 
So far, the class of 
rifamycins is the only clinically used natural RNA polymerase inhibitor [61].
 
However, with the 
emergence of rifamycin-resistant bacteria that even possesses cross-resistance to the other RNA 
polymerase inhibitors, the development of new drug candidates that have different target sites from 
rifamycins is in demand [60,61]. Dithiolopyrrolone class of compounds, such as 2 and 9, could be 
considered to be the warhead for designing the next-generation of RNA polymerase-associated drugs. 
Yakushiji et al. recently developed a series of novel bacterial RNA polymerase inhibitors by 
incorporating holomycin into several myxopyronin skeletons [57]. One of the resulting compounds 
exhibits good antimicrobial activity against Gram-positive bacteria, implying that using the pyrrothine 
as a component to make hybrid-type drugs is a promising direction for novel drugs development. 
4. Total Synthesis of Dithiolopyrrolones 
Total syntheses of dithiolopyrrolones have been attempted since the early 1960s, and many 
synthetic strategies have been developed. 
The first total synthesis of thiolutin (2) and derivatives was achieved in 1962 starting with  
N-methyl-1-ethoxycarbony L-2-diethoxyethylamine and methoxycarbonylacetyl chloride [62]. In 1964, 
Lukas and Buchi proceeded along a different synthetic route with the starting material of  
S-benzyl-L-cysteine ethyl ester but through the same dithiol intermediate as reported in 1962  
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(Scheme 1) [63]. These syntheses of 9, however, have relied on the oxidation of the common 
intermediate, reduced dithiolopyrrolone dithiols, to create the disulfide ring and have not been 
adaptable to the preparation of ring-substituted derivatives [64]. Later on, Ellis et al. devised the 
synthesis of the preparation of holomycin and its 3-carboxylated derivative starting with  
p-methoxyacetophenone and methyl thioglycolate (Scheme 2) [65]. Among these 10-stage synthetic 
steps, highlighted were the two key reactions, construction the substituted pyrrolinone ring by 
cyclization of the methoxalylamine and contraction of the 6-membered dithioketal to the 5-membered 
disulfide ring of 3-carboxyholomycin adapted from the method developed by Kishi and  
co-workers [66]. Holomycin (9) was finally obtained in a single step by cleavage and concomitant 
decarboxylation from 3-carboxyholomycin 9a’ (Scheme 2) [65]. 
Scheme 1. Lukas’s synthesis of holomycin. 
 
Recently an efficient and convenient synthetic route has been developed for the preparation of 9, 
xenorhabdin I (12) and some other analogs thereof (Scheme 3) [67]. The reaction started with  
1,3-dichloroacetone by treatment of p-methoxybenzylthiol (PMBSH) to yield the 12a in a one-pot 
procedure. The amine functionality was next introduced by reaction of 12b with ammonium acetate to 
give 12c in 87% yield. TFA-pyrrothine 12d was generated by refluxing 12c in TFA in the presence of 
m-cresol in order to remove the PMP protecting groups and simultaneously form the pyrrothine 
skeleton. The benefit of this synthetic route would give fast access to an intermediate pyrrothine with a 
free amino, which would ease analog synthesis. Another highlight in this contribution was that this 
method used p-methoxybenzyl (PMB) group instead of t-butyl group as protective group which 
requires the use of toxic and environmentally hazardous mercuric acetate for removal (Scheme 3) [67]. 
  
BzS
NH2
diketene
BzS
N
H
O O
1. NaOEt, C6H6, 3 H
H
O
O
N
H
O
TsCl, THF, 55 °C
1. NaOH, H2OHO NHCOCH3
N
H
O
BzS NHCOCH3
N
H
O
HS NHCOCH3
N
H
O 9
air oxidation
2. rt, 12h
H
O
N
N
H
O
OH
NH2OH
.HCl
NaOAc
H2O
2. Dilute HCl, rt
C7H7SO2O NHCOCH3
N
H
O THF, rt, 12 h
NaOMe, BnSH, EtOH
Li, 6 min
BzS
H
O
O
N
H
O
BzS
OOOO
SOCl2
C6H6
BzS
BzS
BzS
TsCl, Et3N
BzS HS
Mar. Drugs 2013, 11 3980 
 
Scheme 2. Ellis’s synthesis of holomycin (9) and its carboxylated derivative (9a’). 
 
Scheme 3. Hjelmgaard’s synthesis of holomycin and its derivatives. 
 
The downside of the methods presented on Schemes 1–3 are the relatively low yields and lack of 
versatility in providing various derivatives needed for biological studies. Stachel and co-workers 
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demonstrated modified and versatile synthetic routes of preparation of ring-fused dithiinopyrroles, 
dithiolopyrroles and pyrroloisothiazoles [68]. A series of phenyl-substituted dithiolopyrrolones were 
prepared starting from the known lactam pyrrolinone. The key reaction was based on the nucleophilic 
displacement of the methoxy and bromine by Na2S, giving a dithiolate; the latter was readily oxidized 
by O2 in air forming dithiolopyrrolones. Furthermore, the N-methylated derivatives were obtained by 
reacting with MeI (Scheme 4) [69]. 
Scheme 4. Stachel’s synthesis of dithiolopyrrolones. 
 
Li et al. developed an expedient manner (seven steps) of the total synthesis of dithiolopyrrolones 
from commercially available starting materials in a kilogram scale and prepared 17 of dithiolopyrrolone 
derivatives with aromatic substituents on the pyrrolone nitrogen atom (Scheme 5) [70,71]. The key 
step for introduction of N-substituted aromatic group was the reaction of ketone intermediate with the 
appropriate aromatic primary amines in tetrahydrofuran to afford the cyclic enols in good yield  
(60%–70%), followed by the conversion into the corresponding cyclic enamines. The remaining steps 
towards the synthesis of pyrrolones were considerably similar to the ones previously reported [67]. 
Scheme 5. Li’s synthesis of dithiolopyrrolone derivatives. 
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Gao and Hall et al. reported the first total synthesis of a thiomarinol derivative with three 
components, pseudomonic acid, 8-hydroxyoctonoic acid and anhydroornithine [72]. The total yield 
after 13 synthetic steps was 22%. The concise synthetic route of a stereoconvergent three-component 
strategy was considered to be amendable to the design of other analogues, i.e., thiomarinol A. 
5. Biosynthesis of Dithiolopyrrolones 
5.1. Precursor-Directed Biosynthesis (PDB) of Dithiolopyrrolones 
The generation of natural product analogues is often important for improving bioavailability to fine 
tune compounds’ activity [73]. PDB has proven to be a powerful tool for the synthesis of structural 
analogues [74]. PDB takes advantage of the natural flexibility of biosynthetic pathways toward the 
acceptance of unnatural precursor analogues. Analogs of biosynthetic building blocks are designed, 
synthesized and fed to the organism and the biosynthetic enzymes, if in degree of promiscuity, then 
incorporate this unnatural building block into the natural product so that analogs of natural product of 
interests will be generated [74]. 
Saccharothrix algeriensis is a rare actinomycete isolated from the soil of the palm groves of 
Southern Algeria [9]. Five thiolutin-type dithiolopyrrolones with different branched chains and chain 
length of acyl groups were obtained from the fermentation broth of S. algeriensis, implying that there 
may have some degree of plasticity for the enzymes responsible for bioconversion of organic acid into 
acyl-CoA and installation of acyl-CoA into the holothin skeleton. Bouras et al. then explored this 
property by introduction of various organic acids into fermentation media. The addition of only three 
acids, benzoic, valeric and cinnamic acids, led to the production of unnatural dithiolopyrrolones 
identified in the culture broth of S. algeriensis [24]. Of particular interest was the incorporation of 
aromatic acids into the scaffolds of dithiolopyrrolones, indicating the enzyme promiscuity in the 
biosynthetic pathway of dithiolopyrrolones in S. algeriensis (Figure 4). Adding valeric acids into the 
fermentation medium of S. algeriensis also induced the production of three new antibiotic 
dithiolopyrrolones, formylpyrrothine 28, valerylpyrrothine 29 and isovalerylpyrrothine 30 [75]. 
Further exploitation of PDB method led to identification of four new dithiolopyrrolone antibiotics, 
crotonylpyrrothine 31, sorbylpyrrothine 32, 2-hexenylpyrrothine 33 and 2-methyl-3-pentenylpyrrothine 34, 
in the presence of 5 mM sorbic acid in the production medium, showing the remarkable flexibility of 
the dithiolopyrrolone biosynthetic pathway in S. algeriensis [76]. 
Recent genome sequencing of the thiomarinol producer bacterium Pseudoalteromonas sp. SANK 
73390 indicated that thiomarinols are biosynthesized from two independent pathways, an AT-less  
type I PKS one for marinolic acid and a NRPS one for holothin [77]. Inactivation of one of domains in 
PKS genes resulted in the PKS mutant in which the production of thiomarinols was completely 
abolished. Feeding pseudomonic acid A (0.1 mg mL
−1
) immediately after inoculation resulted in 
identification and isolation of two new derivatives, a pyrrothine derivative of pseudomonic acid 35 and 
its 4-hydroxylated analogue 36 along with three derivatives of pseudomonic acid A (Figure 4) [15]. 
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Figure 4. “Unnatural” dithiolopyrrolone natural products using precursor-directed biosynthesis. 
 
5.2. Biosynthesis of Dithiolopyrrolones 
Despite the emerging importance of dithiolopyrrolones, the dearth of the biosynthetic knowledge 
was particularly striking until recently. The difficulty to locate constituent gene segments even if they 
were clustered may result from the unusual heterobicyclic and highly oxidative dithiolopyrrolone 
skeleton. Early feeding experiment demonstrated that L-cystine appeared to be the precursor of 
dithiolopyrrolone biosynthesis and that pyrrothine seemed to be an intermediate in the pathway from 
L-cystine to dithiolopyrrolone [78,79]. 
It has been speculated that an N-acetyltransferase type of enzyme could be involved in the late stage 
of the holomycin biosynthesis. Indeed, the presence of such an enzyme appeared to be necessary for 
the amide bond formation between the holothin nucleus (deacetylholomycin) and acetylCoA in cell-free 
extracts of the holomycin-overproducing mutants of S. clavuligerus [80]. A similar result was also 
shown that incubation with N-methylpyrrothine and acetylCoA or benzoylCoA in the cell-free extract 
of S. algeriensis NRRL-24137 resulted in formation of thiolutin or N-methyl-N-benzoylpyrrothin, 
respectively [81]. 
5.2.1. Identification of the Holomycin Gene Cluster in S. clavuligerus 
Analysis of Streptomyces clavuligerus genome sequence indicated that S. clavuligerus has a 
relatively small chromosome of 6.8 Mb in length but contains a megaplasmid of 1.8 Mb in length [82]. 
There are 48 putative secondary metabolite gene clusters that have been identified by a homolog 
comparison. Among these gene clusters, 23 are in the chromosome and 25 are in the megaplasmid. 
Taken advantage of the genome mining strategy, the holomycin biosynthetic gene cluster in  
S. clavuligerus has recently been identified and characterized, as evidenced through heterologuous 
protein expression, enzyme activity assays [83] and heterologuous expression of the gene  
cluster [84,85]. 
The holomycin gene cluster consists of 12 genes, spanning an approximately 17.6 kb region in the 
chromosome of S. clavuligerus, ten of which the functions have been assigned (Figure 5,  
Table 3) [83,84]. The gene cluster only contains a gene (orf3488 [83] and homE [84]) encoding a 
multidomain non-ribosomal peptide synthetase (NPRS) with a conical order of cyclization (Cy), 
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adenylation (A) and thiolation domains (T). Of particle interest is that the gene cluster also encodes 
four flavin-dependent oxidoreductases (ORF3483, 3487, 3489, 3492 [83] or HomB, D, F, I [86]) and a 
putative acetyltransferase (ORF 3484 [83] or HomA [84]). Additionally, three stand-alone NRPS 
encoded proteins were found in the gene cluster. These are freestanding C domain (ORF3495 [83] or 
HomK [84]), the Te Domains (ORFs 3486 and 3494 [83] and HomC and HomJ [84]). Two genes in 
the cluster, orf 3491 and 3496 (homH and homL [84]), respectively, were predicted to be a regulatory 
gene and transporter gene, respectively. 
Figure 5. Comparison of the genetic organization of the holomycin biosynthetic gene 
clusters from S. clavuligerus, Y. ruckeri and Pseudoalteromonas, respectively. 
 
Table 3. Deduced functions of open reading frames (ORFs) that were predicted to be 
involved in the biosynthesis of holomycin in S. clavuligerus, Y. ruckeri and 
Pseudoalteromonas, respectively. 
ORFs in  
S. clavuligerus [83] 
Homolog in Y. ruckeri 
(Identity %) [38] 
Homolog in Pseudoalteromonas 
(Identity %) [87] 
Proposed Function 
ORF3489(HlmF) Hom1 (61%) HolG (72%) PPC-DC decarboxylase 
ORF3490(HlmG) Hom2(65%) HolF (70%) Globin 
ORF3483(HlmA) Hom3 (38%) HolE (45%) N-acyltransferase 
ORF3485(HlmB) Hom4 (58%) HolD (63%) Acyl-CoA dehydrogenase 
ORF3486(HlmC) Hom5 (36%) HolC (42%) Thioesterase 
ORF3487(HlmD) Hom6 (47%) HolB (59%) FMN-dependent oxdioreductase 
ORF3488(HlmE) Hom7 (47%) HolA (55%) NRPS (Cy-A-T) 
ORF3491(HlmH) Hom8 (61%) 
 
MFS efflux protein 
Gene disruption of orfs 3488 and 3489 in the holomycin-overproducing mutant completely 
abolished holomycin production, indicating that the identified gene cluster is responsible for 
holomycin production [83]. We also demonstrated that introduction of the whole gene cluster into a 
heterologuous host Streptomyces albus resulted in the production of holomycin in the mutant  
S. albus [84]. 
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5.2.2. Characterization of Key Enzymes during the Holomycin Biosynthesis in S. clavuligerus 
Given that genetic evidence demonstrated the involvement of ORF3488 for the holomycin 
production, it was overproduced in E. coli. The amino acid-dependent exchange assay showed that the 
adenylation domain of ORF3488 proceeds aminoacylation of L-cysteine but not the other 
proteinogenic amino acid with a Km value of 1 mM and a Kcat value of 98 min
−1 
[83]. 
The predicated activity of the encoded ORF3483 was an N-acetylCoA transferase. Incubation of 
recombinant ORF3483 (10 nM) with acetylCoA and holothin (20 nM) showed the formation of 
holomycin with an apparent Km of 6 nM and a Kcat of 80 min
−1
, reassuring the involvement of 
ORF3483 during the biosynthesis of holomycin (Scheme 6). Surprisingly, recombinant ORF3483 was 
also able to utilize longer chain acyl CoAs (hexanoyl, octanoyl and palmitoylCoA) as substrates with 
less efficiency. The apparent Km of 30 nM and apparent kcat of 0.07 min
−1
 was obtained from 
octanoylCoA in the presence of 20 nM holothin [83].
 
Longer chained acyl holothins were not observed 
in the fermentation broth of S. clavuligerus presumably because the pools of these fatty acids or 
acylCoAs could be very low. Identification of longer acyl chain variants of dithiolopyrrolones, 
however, was observed in other microorganisms [9,16]. 
Scheme 6. Biochemical study confirmed that the N-acetyl-CoA transferase ORF3483 is 
responsible for the amid bond formation at the late stage of the holomycin biosynthesis in 
Streptomyces clavuligerus. 
 
It is rare for molecular scaffolds of bacterial natural products to contain disulfide bonds, and the 
mechanism of disulfide bond formation in these products is poorly understood until recently [86]. The 
first evidence of the disulfide bond formation was reported in 2009 during the study of the biosynthesis 
of FK228, a disulfide-containing anticancer despeptide natural product isolated from the soil 
bacterium, Chromobacterium violaceum 968. The identified enzyme DepH represents a new subclass 
of the thioredoxin protein superfamily [86]. In 2010, another homolog enzyme GliT was found to be 
responsible for the disulfide-bond formation in the biosynthesis of Gliotoxin, a disulfide-containing 
metabolite isolated from the human pathogen Aspergillus fumigatus [88]. Although both DepH and 
GliT belong to a new member of FAD-dependent dithiol oxidases, DepH utilizes NADP
+
 as the 
electron acceptor [86] while GliT use O2 to promote the disulfide formation [88]. 
In silica analysis of the holomycin gene cluster in S. clavuligerus showed that the encoded 
flavoenzyme HlmI [89] (ORF3492 [83] and HomI [84]) may function analogously to DepH or GliT to 
convert dithiol form of reduced holomycin 9b’/holothin 9b into holomycin 9/holothin 9a (Scheme 7). 
Indeed, incubation of purified recombinant HlmI (50 nM) with FADH2 and reduced holomycin 9b’  
(5–100 nM) led to the rapid formation of holomycin in presence of oxygen with an apparent Km of  
4.6 ± 1.9 nM and an apparent kcat of 333 ± 28 min
−1
. Although HlmI clearly accelerated the disulfide 
Mar. Drugs 2013, 11 3986 
 
bond formation from reduced holothin 9b to holothin 9a, the nonenzymatic oxidation in presence of 
oxygen precluded kinetic measurement [89]. It was concluded that HlmI is a GliT-like FAD-dependent 
dithiol oxidase, using O2 as the oxidative agent for the formation of intramolecular disulfide bridges in 
the late stage of the holomycin biosynthesis [89]. 
Scheme 7. Biochemical study confirmed that the dithiol oxidase HlmI is responsible for 
the disulfide bond formation using molecular oxygen as a cofactor. 
 
5.2.3. Regulation of the Biosynthesis of Holomycin in S. clavuligerus 
Regulation of the holomycin production in Streptomyces appeared to be very complex. Early 
studies indicated that holomycin production appeared to be associated with the production of 
cephamycin C. For example, the wild type Streptomyces sp. P6621 produces cephamycin C but does 
not produce 9. Chemical mutagenesis of Streptomyces sp. P6621 resulted in the production of 9 and 
the reduced yield of cephamycin C [32]. The wild type S. clavuligerus only produces trace amount of 
holomycin. UV mutagenesis led to generate the mutant IT1 that was a holomycin-overproducing  
strain [29]. In 2001, Liras et al. demonstrated that gene knockout in the gene cluster of clavulanic acid 
in S. clavuligerus resulted in overproduction of holomycin, suggesting that the intriguingly intricate 
cross-regulation between the biosynthetic pathways of clavulanic acid and holomycin [80]. 
A rhodanese-like protein was found to be highly overrepresented in the proteome of the  
holomycin-overproducing mutant of Streptomyces clavuligerus. Disruption of the rhodanese-like gene 
resulted in great loss of holomycin production in the rhlA mutants [90]. 
Addition of arginine appears to stimulate the production of holomycin [91,92]. The gene argR is a 
universally conserved repressor gene in the arginine biosynthesis in S. clavuligerus NP1. Disruption of 
argR resulted in holomycin-overproducing mutant, S. clavuligerus CZ [93]. Comparative proteomic 
studies demonstrated that the expression levels of proteins involved in acetyl-CoA and cysteine 
biosynthesis increased in the mutant CZR strain, consistent with the holomycin overproduction 
phenotype [93]. 
The genes afsR and afsS in S. clavuligerus ATCC27064 encode proteins resembling the well-known 
antibiotic biosynthetic activators. It was found that re-introduction of afsRScla genes into the wild-type 
S. clavuligerus activated the normally silent holomycin biosynthetic gene cluster while the production 
of clavulanic acid was also increased 5-fold in resultant mutant compared to the wild-type strain [94]. 
A competition-based adaptive laboratory evolution could accelerate the discovery of antibiotics 
when an antibiotic-producing microorganism is competed against a drug-resistant pathogen [95]. Of 
particular interest is that actinomycetes that are well known producer of secondary metabolites could 
adaptively evolved in the laboratory to produce new antibacterial compounds, of which the production 
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is silent in the normal laboratory culture conditions [96]. Palsson et al. demonstrated that, after several 
rounds of co-culturing S. clavuligerus and the methicillin-resistant Staphylococcus aureus (MRSA) 
N315, a mutant strain of S. clavuligerus emerged that acquired the ability to constitutively produced 
holomycin, the antibacterial agent that inhibits the growth of MRSA [97]. Genome sequencing 
revealed that the mutant strain had lost the megaplasmid, and acquired genetic mutations that affected 
secondary metabolite biosynthesis [97]. 
More recently, RT-PCR transcription analysis of the holomycin-overproducing mutant of  
S. clavuligerus showed a higher transcription of some genes in the holomycin gene cluster compared 
with the ones in the wild-type strain [85]. This result was consistent with the proteomic analysis of the 
holomycin overproducer mutant that some transcribed proteins related to the holomycin pathway were 
overexpressed [85]. 
5.2.4. Identification of the Holomycin Gene Cluster in the Fish Pathogen Yersinia ruckeri 
Homolog search indicated that several open reading frames (ORFs) in the genome of the fish 
pathogen Yersinia ruckeri appear to be homologous to the ones in the holomycin pathway of  
S. clavuligerus, including three oxidoreductases, one thioesterase and, more importantly, one 
multidomain NRPS with a conical order of Cy-A-T arrangement. However, this gene cluster lacks two 
key homolog genes, one encoding the dithiol oxidase that promotes the disulfide bridge formation and 
the other encoding the freestanding condensation domain. Our chemical isolation and structural 
elucidation demonstrated that Y. ruckeri is a producer of holomycin. Gene disruption of hom6, a 
homolog of homD [84], completely abolished the production of holomycin in the mutant strain, 
suggesting that the identified gene cluster directs the biosynthesis of holomycin. 
5.2.5. The Proposed Mechanism of the Formation of Holomycin 
Despite the differences between two holomycin gene clusters from the Gram-positive bacterium  
S. clavuligerus and the Gram-negative bacterium Y. ruckeri, the underlying chemical logic of 
holomycin formation should be similar (Scheme 8). 
Biochemical and genetic evidence demonstrated that the formation of holomycin should follow the 
same chemical logic as other biosynthetic pathways of non-ribosomal peptides in which a tridomain 
non-ribosomal peptide synthetase (HomE [84] or HlmE [83] or Hom7 [38]) first selects and activates 
L-cysteine. The condensation activity was proposed to follow an unusual pathway [98]. In  
S. clavuligerus, it was proposed that the flavin-dependent acyl-CoA dehydrogenase (HomB [84] or 
HlmB [83]), the standalone C domain and the Cy domain of the NRPS are responsible for oxidizing, 
coupling, and cyclizing two cysteine residues to yield a cyclodithiol-PCP-domain tethered intermediate 
9f. In Y. ruckeri, no dedicated C domain can be found within the holomycin gene cluster. Thus the Cy 
domain may have dual functions that catalyze both condensation and cyclization of C-C formation, 
although it clearly remains speculative until the studies of the detailed mechanism is carried out [38]. 
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Scheme 8. Proposed biosynthetic pathway of holomycin. 
 
The cyclodithiol-PCP-domain tethered intermediate 9f could then be hydrolyzed by the thioesterase 
(HomC [84] or HlmC [83] or Hom5 [38]) to generate the free acid intermediate 9e. The  
glucose-methanol-choline oxidoreductase homolog (HomD [84] or HlmD [83] or Hom6 [38]) could be 
responsible for the 2-electron oxidation step on 9d into 9c. HomF [84] (HlmF [83] or Hom1 [38]) is an 
analog of phosphopantothenoylcystein decarboxylase in coenzyme A biosynthesis. In the reaction 
cycle of PPC-DC, the thiol moiety of pantothenoylcysteine is first oxidized and spontaneously 
decarboxylatedto generate the pantothenoylaminoethenethiol intermediate, which is finally reduced to 
form pantothenoylcysteamine. In analogy, HomF [84] (HlmF [83] or Hom1 [38]) could catalyze the 
decarboxylation of the intermediate 9c into 9b. The assignment does not, however, suggest a preferred 
sequence for these activities [83]. In S. clavuligerus, HlmI appeared to play important roles in the 
biosynthesis of holomycin.
 
Li et al. has confirmed that recombinant HlmI mediates the disulfide bond 
formation from reduced holomycin 9a to holomycin 9 using O2 as cofactor, and it was proposed that 
HlmI is involved in the late stages of holomycin biosynthesis [89]. Gene disruption of hlmI resulted in 
decreased production of holomycin and increased sensitivity toward holomycin [89]. The homolog of 
HlmI, however, cannot be found in the holomycin gene cluster in Y. ruckeri and a similar absence was 
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also observed in the thiomarinol gene cluster from Pseudoalteromonas sp. SANK73390, indicating the 
different underlying chemical logic of disulfide bond formation in Gram-negative bacteria [38]. 
Biochemical evidence demonstrated that HlmA is responsible for the acylation of the amino group in 
holothin 9b or reduced holothin 9a [83]. 
5.3. Biosynthesis of Thiomarinol Natural Products 
Thiomarinols belong to a special group of dithiolopyrrolones in that they are hybrid antibacterial 
compounds consisting of three components, a pseudomonic acid moiety esterified by a  
terminal-hydroxy fatty acid (n = 7 or 9) attached to the holothin moiety via an amide linkage. 
Recently genome sequence of the thiomarinol-producer bacterium revealed a novel plasmid, 
pTML1 with the length of 97 kbp [87]. Interestingly, the plasmid contains two distinct gene clusters, 
one responsible for the biosynthesis of pseudomonic acid and the other for the holothin moiety. The 
pseudomonic acid gene cluster contains the typical feature of trans-AT/AT-less polyketide synthase 
(PKS) assembly line in that the encoded multidomain PKSs do not contain dedicated acyltransferase 
domain to activate the acyl substrate. The gene cluster for holothin moiety is similar to the one in  
Y. ruckeri, consisting of 7 genes encoding a multidomain NRPS HolA (Cy-A-T, homolog to Hom7), 
an oxidoreductase HolB (homolog to Hom6), a thioesterase HolC (homolog to Hom5), a 
dehydrogenase HolD (homolog to Hom4), a N-acyltrasferase HolE (homolog to Hom3), an  
flavin-dependent oxygenase HolF (homolog to Hom2) and a decarboxylase HolG (homolog to Hom1), 
respectively (Figure 5). It appeared that the chemical logic for holothin scaffold during the 
biosynthesis of thiomarinols should be the same as the one of holomycin. Inactivation of holA resulted 
in completely loss of thiomarinol but the only production of marinolic acid in the mutant strain [77], 
confirming that the hol gene cluster is responsible for the holothin biosynthesis, and marinolic acids 
and dithiolopyrrolones are biosynthesized from two independent pathways. 
In the late stage of the holomycin biosynthesis from both S. clavuligerus and Y. ruckeri, acyl-CoA 
was proposed to be the substrate of the acyl CoA transferase that mediates the amide bond formation 
for the holomycin production. In the thiomarinol biosynthesis, TmlU was assigned as an  
ATP-dependent ligase, a homolog of SimL in the simocylinone biosynthesis [77,99] and NovL in the 
novobiocin biosynthesis that catalyze the amide bond forming activity with a variety of carboxylic 
acids [100]. Inactivation of tmlU completely abolished the production of thiomarinols but resulted in 
the production of xenorhabdins and marinolic acids, pseudomonic acid derivatives, thus suggesting its 
role of linking the pseudomonic acid and holothin to generate thiomarinols. The production of 
xenorhabdins and derivatives, however, indicates that HolE, a homolog of acylCoA transferase, could 
be the second copy of amide-formation enzyme responsible for the installation of acylCoA into the 
amino group of holothin to generate xenorhabdins 14–20 (Scheme 9). 
  
Mar. Drugs 2013, 11 3990 
 
Scheme 9. Proposed biosynthetic pathway of thiomarinol A. 
 
6. Conclusions 
The family of dithiolopyrrolone natural products has attracted attention from the research 
communities of natural product chemistry/biosynthesis, synthesis and microbiology on their unique 
chemical identity and multiple biological activities. There have been challenging questions of the 
biosynthesis, the complex regulation network and the mode of action of this novel class of molecules 
during the last decade. Recent efforts on the biosynthetic pathways of holomycin and thiomarinols 
have just started to uncover the intriguing aspects of the underlying chemical logic, regulation and 
resistance of this class of molecules. This review article has covered the natural product discovery, 
synthesis, bioactivity and biosynthesis of this class of natural products in the first time over sixty years. 
Further progress in this class of molecules will be to understand the biochemistry of the formation of 
the pyrrolone chromophore and the timing of N-methylation in thiolutin-type of molecules, and to 
ascertain the exact antibacterial mode of action, which will facilitate a greater understanding of this 
promising class of antibacterial and antitumor agents. 
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